Comparison of Adjuvant Trastuzumab Courses for Early HER2-Positive Breast Cancer

We'll start off with an analysis of 9 weeks vs 1 year of adjuvant trastuzumab for patients with early HER2-positive breast cancer. Then, we’ll review a retrospective cohort study that aimed to quantify cancer screening deficits in the United States associated with the COVID-19 pandemic.

---